Use of Airpod Pros as Assistive Technology

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this study is to investigate the suitability and effectiveness of the AirPod Pro 2nd and 3rd generation (AP) as hearing assistive technology for individuals with mild-to-moderate hearing loss when listening in noisy environments. Researchers will compare four types of assistive technology: hearing aids (HAs), AP, dedicated wireless remote microphones, and Smartphone wireless remote microphone. The main questions it aims to answer are: * Which assistive technology provides the greatest benefit for speech recognition in noisy environments? * How do these devices impact listening effort, as measured by reaction time in a dual-task activity and changes in pupil size? * What are participants' preferences for each device based on how easy it is to understand speech and their overall satisfaction? Participants will visit the lab for a single 3-hour session. They will listen to sentences using each device and repeat what they hear. During this task, their reaction times for the secondary task and changes in pupil size will be measured.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Adults aged 18 to 60 years.

• Native English speakers.

• Mild-to-moderate hearing loss confirmed by a pure-tone hearing test (average hearing threshold screening 25 to 55 dB HL across octave frequencies from 250 to 8000 Hz).

• Individuals with no prior hearing aid experience for a year.

Locations
United States
Texas
Callier Center for Communication Disorders
RECRUITING
Richardson
Contact Information
Primary
Linda Thibodeau, Ph.D.
thib@utdallas.edu
972-883-3108
Backup
Seeon Kim, Ph.D.
Seeon.Kim@utdallas.edu
4806164403
Time Frame
Start Date: 2025-07-01
Estimated Completion Date: 2026-01
Participants
Target number of participants: 24
Treatments
Experimental: Treatment group
AP, HA, ... (Randomized)
Related Therapeutic Areas
Sponsors
Leads: The University of Texas at Dallas

This content was sourced from clinicaltrials.gov

Similar Clinical Trials